CL2023001398A1 - Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística. - Google Patents
Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística.Info
- Publication number
- CL2023001398A1 CL2023001398A1 CL2023001398A CL2023001398A CL2023001398A1 CL 2023001398 A1 CL2023001398 A1 CL 2023001398A1 CL 2023001398 A CL2023001398 A CL 2023001398A CL 2023001398 A CL2023001398 A CL 2023001398A CL 2023001398 A1 CL2023001398 A1 CL 2023001398A1
- Authority
- CL
- Chile
- Prior art keywords
- modulators
- cystic fibrosis
- conductance regulator
- transmembrane conductance
- fibrosis transmembrane
- Prior art date
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title abstract 3
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title abstract 3
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 title 1
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115552P | 2020-11-18 | 2020-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001398A1 true CL2023001398A1 (es) | 2023-11-24 |
Family
ID=79602287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001398A CL2023001398A1 (es) | 2020-11-18 | 2023-05-16 | Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4247817A1 (zh) |
| JP (1) | JP2023549547A (zh) |
| KR (1) | KR20230123522A (zh) |
| CN (1) | CN116670140A (zh) |
| AR (1) | AR124090A1 (zh) |
| AU (1) | AU2021383176A1 (zh) |
| CA (1) | CA3201793A1 (zh) |
| CL (1) | CL2023001398A1 (zh) |
| CO (1) | CO2023007896A2 (zh) |
| CR (1) | CR20230260A (zh) |
| DO (1) | DOP2023000099A (zh) |
| EC (1) | ECSP23045439A (zh) |
| IL (1) | IL302873A (zh) |
| MX (1) | MX2023005721A (zh) |
| PE (1) | PE20231380A1 (zh) |
| WO (1) | WO2022109573A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150237A1 (en) * | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
| WO2023224931A1 (en) * | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| WO2024054851A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
| WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
| WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
| WO2024056791A1 (en) * | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5886433B2 (ja) * | 2011-09-16 | 2016-03-16 | ノバルティス アーゲー | 嚢胞性線維症処置のためのヘテロ環式化合物 |
| US11066417B2 (en) * | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
-
2021
- 2021-11-17 EP EP21843853.9A patent/EP4247817A1/en active Pending
- 2021-11-17 CA CA3201793A patent/CA3201793A1/en active Pending
- 2021-11-17 WO PCT/US2021/072475 patent/WO2022109573A1/en active Application Filing
- 2021-11-17 CR CR20230260A patent/CR20230260A/es unknown
- 2021-11-17 PE PE2023001653A patent/PE20231380A1/es unknown
- 2021-11-17 AU AU2021383176A patent/AU2021383176A1/en active Pending
- 2021-11-17 JP JP2023529022A patent/JP2023549547A/ja active Pending
- 2021-11-17 MX MX2023005721A patent/MX2023005721A/es unknown
- 2021-11-17 IL IL302873A patent/IL302873A/en unknown
- 2021-11-17 KR KR1020237020002A patent/KR20230123522A/ko unknown
- 2021-11-17 CN CN202180090910.1A patent/CN116670140A/zh active Pending
- 2021-11-18 AR ARP210103184A patent/AR124090A1/es unknown
-
2023
- 2023-05-16 CL CL2023001398A patent/CL2023001398A1/es unknown
- 2023-05-17 DO DO2023000099A patent/DOP2023000099A/es unknown
- 2023-06-16 CO CONC2023/0007896A patent/CO2023007896A2/es unknown
- 2023-06-16 EC ECSENADI202345439A patent/ECSP23045439A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021383176A1 (en) | 2023-06-22 |
| ECSP23045439A (es) | 2023-08-31 |
| CA3201793A1 (en) | 2022-05-27 |
| PE20231380A1 (es) | 2023-09-07 |
| KR20230123522A (ko) | 2023-08-23 |
| MX2023005721A (es) | 2023-07-25 |
| EP4247817A1 (en) | 2023-09-27 |
| IL302873A (en) | 2023-07-01 |
| AR124090A1 (es) | 2023-02-15 |
| CR20230260A (es) | 2023-10-05 |
| WO2022109573A1 (en) | 2022-05-27 |
| CO2023007896A2 (es) | 2023-09-18 |
| DOP2023000099A (es) | 2023-08-15 |
| CN116670140A (zh) | 2023-08-29 |
| JP2023549547A (ja) | 2023-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023007896A2 (es) | Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| UY39374A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| UY39457A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| UY39460A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| UY39458A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| UY39459A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| UY39461A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| UY39456A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| CO2022002749A2 (es) | Moduladores del regulador de conductancia transmembrana de la fibrosis quística | |
| UY39455A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
| DOP2023000016A (es) | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos | |
| AU2017298354A1 (en) | Aerosol generating apparatus | |
| BR112022016799A2 (pt) | Composição, fibra, pano não tecido, uso de uma composição, e, composto | |
| UY39521A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| WO2018088791A3 (ko) | 음압발생장치 및 이를 이용한 압력변화기능을 갖는 자동음압 상처치료기 | |
| BR112019005662A2 (pt) | dispositivo de vaporizador resistente a vazamentos |